ArticleJournal of cellular and molecular medicine2014
CD34+ VEGFR-3+ progenitor cells have a potential to differentiate towards lymphatic endothelial cells.
Article in Journal of cellular and molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Crosstalk between lymphatic system and synovial inflammatory cells in osteoarthritis: molecular mechanisms and potential cell-based therapies.Journal of translational medicine · 2025Review
- Telocytes: history, origin, identification, structure, distribution, and functions.Histochemistry and cell biology · 2025Review
- IGF-1 secreted by mesenchymal stem cells affects the function of lymphatic endothelial progenitor cells: a potential strategy for the treatment of lymphedema.Frontiers in genetics · 2025Article
- Telocytes: current methods of research, challenges and future perspectives.Cell and tissue research · 2024Review
- Therapeutic Lymphangiogenesis Is a Promising Strategy for Secondary Lymphedema.International journal of molecular sciences · 2023Review
- KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi's sarcoma studies.PLoS pathogens · 2023Article
- CD34 positive cells as endothelial progenitor cells in biology and medicine.Frontiers in cell and developmental biology · 2023Review
- Lymphatic Tissue and Organ Engineering for In Vitro Modeling and In Vivo Regeneration.Cold Spring Harbor perspectives in medicine · 2022Article
- Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Enhancement of cardiac lymphangiogenesis by transplantation of CD34Basic research in cardiology · 2019Article
- Endothelial Cell Development and Its Application to Regenerative Medicine.Circulation research · 2019Review
- Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges.Journal of clinical medicine · 2019Review
- Functional Heterogeneity of Endothelial Cells Derived from Human Pluripotent Stem Cells.Stem cells and development · 2018Article
- Multipotent Adult Progenitor Cells Support Lymphatic Regeneration at Multiple Anatomical Levels during Wound Healing and Lymphedema.Scientific reports · 2018Article
- Hypoxic preconditioning-induced autophagy enhances survival of engrafted endothelial progenitor cells in ischaemic limb.Journal of cellular and molecular medicine · 2017Article
- Novel role of immature myeloid cells in formation of new lymphatic vessels associated with inflammation and tumors.Journal of leukocyte biology · 2017Review
- Lymphatic endothelial progenitors originate from plastic myeloid cells activated by toll-like receptor-4.PloS one · 2017Article
- Autophagy promotes degradation of polyethyleneimine-alginate nanoparticles in endothelial progenitor cells.International journal of nanomedicine · 2017Article
- Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.The American journal of pathology · 2016Article
- Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome.Journal of cellular and molecular medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial progenitor cells (EPCs) play an important role in postnatal neovascularization. However, it is poorly understood whether EPCs contribute to lymphangiogenesis. Here, we assessed differentiation of a novel population of EPCs towards lymphatic endothelial cells and their lymphatic formation. CD34(+) VEGFR-3(+) EPCs were isolated from mononuclear cells of human cord blood by fluorescence-activated cell sorting. These cells expressed CD133 and displayed the phenotype of the endothelial cells. Cell colonies appeared at 7-10 days after incubation. The cells of the colonies grew rapidly and could be repeatedly subcultured. After induction with VEGF-C for 2 weeks, CD34(+) VEGFR-3(+) EPCs could differentiate into lymphatic endothelial cells expressing specific markers 5'-nucleotidase, LYVE-1 and Prox-1. The cells also expressed hyaluronan receptor CD44. The differentiated cells had properties of proliferation, migration and formation of lymphatic capillary-like structures in three-dimensional collagen gel and Matrigel. VEGF-C enhanced VEGFR-3 mRNA expression. After interfering with VEGFR-3 siRNA, the effects of VEGF-C were diminished. These results demonstrate that there is a population of CD34(+) VEGFR-3(+) EPCs with lymphatic potential in human cord blood. VEGF-C/VEGFR-3 signalling pathway mediates differentiation of CD34(+) VEGFR-3(+) EPCs towards lymphatic endothelial cells and lymphangiogenesis. Cord blood-derived CD34(+) VEGFR-3(+) EPCs may be a reliable source in transplantation therapy for lymphatic regenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.